



DEVELOPMENT OF AN INNOVATIVE TREATMENT METHODOLOGY FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE

**Prof Dr.G.Manoj
Someswar**

Director General & Scientist 'H', Global Research Academy – Scientific & Industrial Research Organisation [Autonomous], Hyderabad, Telangana State, India

ABSTRACT

It has been a clinical test to treat Alzheimer's infection (AD). In the present editorial we examine whether home grown treatment could be a novel treatment technique for AD on the premise of results from clinical trials, and talk about the suggestions for potential treatment for AD pathophysiology. There is confirmation to recommend that solitary herbs or home grown plans may offer certain integral intellectual advantages to the endorsed drugs. The present confirmation supporting their utilization alone, in any case, is uncertain or deficient attributable to numerous methodological constraints. Herbal plants varieties may have focal points with numerous objective direction contrasted and the single-target foe in the perspective of conventional Chinese solution. A few clinical trials utilizing home grown blends are being led in China and will ideally indicate promising outcomes for treating AD sooner rather than later.

KEYWORDS : Alzheimer Disease (AD), Alzheimer Disease Assessment Scale (ADAS), Dementia, Cholinesterase inhibitors, Neuropsychiatric Inventory, amyloid cytotoxicity, Barthel Index

Introduction

A definitive point of Alzheimer's infection (AD) treatment is to stop or back off the illness movement. Cholinesterase inhibitors have an unobtrusive clinical impact on the indications, notwithstanding, and memantine - the as of now accessible N-methyl-D-aspartate receptor rival - does not keep the weakening of dementia [1, 2]. Finding a compelling technique to treat AD still represents a huge clinical test.

Herbal medicines have for quite some time been utilized as a part of Chinese system of treatment for dementia. The Complete Work of Jingyue distributed in 1624 contains the most punctual known

depiction in the realm of a herbal remedial procedure for dementia. In the previous 10 years, be that as it may, herbal medications have occasionally been affirmed for utilize alone in treating dementia. By and large, orderly survey has distinguished a couple of single herbs and natural details as conceivable compelling pharmaceutical for AD (Table 1). As indicated by the present confirmation, some of these treatments demonstrate promising outcomes as far as their psychological advantages. In the present analysis, we talk about whether herbal treatment could be a novel pathway to treat AD, on the premise of the outcomes from clinical trials and the suggestions for potential treatment of AD pathophysiology.

Table 1: Different herbs and formulations effective in the treatment of Alzheimer's disease

Product	Composition	Design	Outcome measure	Source
Huperzine A	An extract from Lycopodium	A 12-week randomized, double-blind, placebo-controlled trial	ADAS-cog, MMSE, CIBIC-plus, ADL of patients with mild to moderate AD	Zhang and colleagues [7]
Ginkgo Biloba	EGb 761	A 24-week randomized, placebo-controlled, double-blind study	MMSE and CGI in patients with mild to moderate AD	Mazza and colleagues [4]
Panax ginseng	Ginsenosides	A 12-week open-label, randomized double-blind, placebo-controlled study	ADAS and MMSE scores of AD patients	Lee and colleagues [17]
Salvia officinalis	Leaf extract containing monoterpene, flavonoids, polyphenol	A 4-month, parallel-group, placebo-controlled trial	ADAS-cog and CDR in patients with mild to moderate AD	Akhondzadeh and colleagues [11]
Ba Wei Di Hunag Wan	Powder of Rehmannia with another seven plants mixed with honey	An 8-week randomized, double-blind, placebo-controlled trial	MMSE and Barthel Index scores in patients with mild to severe dementia	Iwasaki and colleagues [15]
Yi-Gan San formula	A mixture of seven different rootstock and branches, lyophilized dry extract	A 4-week randomized, observer-blind, controlled trial	NPI and ADL in patients with mild to severe dementia	Iwasaki and colleagues [16]

AD, Alzheimer disease; ADAS-cog, Alzheimer disease assessment scale-cognitive subscale; ADL, activities of daily living; CDR, Clinical Dementia Rating; CGI, Clinical Global Impression; CIBIC-plus, Clinician's Interview-Based Impression of Change plus Caregiver Input; MMSE, mini-mental state examination; NPI, Neuropsychiatric Inventory.

Single herbs or extracts from herbs

Ginkgo biloba

Ginkgo biloba extract is among the most broadly utilized integral treatments. A Cochrane audit included 36 trials of ginkgo biloba, however most trials were little and of span <3 months [3]. Nine trials were of a half year length and of satisfactory size, and were led to a sensible standard. Of the four latest trials to report comes about, three investigations found no contrast between Ginkgo biloba, at

various measurements, and fake treatment [3], and one examination discovered huge treatment impacts for Ginkgo biloba, yet the trial test estimate was little [4]. Another current trial revealed negative outcomes in lessening psychological decrease in more established grown-ups with typical insight or with gentle subjective debilitation [5]. The present general confirmation that Ginkgo has an anticipated and clinically critical advantage for individuals with dementia or intellectual weakness subsequently appears to be conflicting and untrustworthy.

Serrate clubmoss

Huperzine A which is extracted from the serrate clubmoss herb is a powerful, reversible and specific inhibitor of acetyl-cholinesterase. Considering the accessible proof from six trials, Huperzine A appears to have some helpful consequences for development of

general subjective capacity, worldwide clinical status, behavioural unsettling influence and useful execution, with no undeniable genuine unfriendly occasions for patients with AD [6]. Just a single report was of sufficient quality and size, however the period amid this examination that discovered substantial treatment impacts was just 12 weeks [7]. In general the present confirmation supporting clinical utilization of Huperzine A is by and by uncertain or lacking.

Ginseng

Panaxi ginseng's primary dynamic fixing is panaxsaponin, which can upgrade psychomotor and subjective execution, and can profit AD by enhancing mind cholinergic capacity, diminishing the level of A β and repairing harmed neuronal systems [8]. The high-measurements ginseng amass indicated measurably huge change on the Alzheimer Disease Assessment Scale (ADAS) and Clinical Dementia Rating (however not on the Mini-Mental State Examination) toward the finish of the investigation, when contrasted and the control gathering. This examination was ineffectively outlined, with an inadequate depiction of randomization and without blinding. Moreover, the specimen measure was little ($n = 15$ for each gathering), and there was likewise a bewildering impact because of simultaneously directed western solutions [9]. The confirmation for ginseng as a treatment of AD is subsequently rare and uncertain. Encourage thorough trials appear justified [10].

Salvia officinalis

Salvia officinalis has been utilized as a part of home grown drug for a long time. Following 4 months of treatment, salvia officinalis remove delivered a fundamentally preferable result on subjective capacities over fake treatment - as observed on the ADAS intellectual subscale and the Clinical Dementia Rating Sum of Boxes scale in patients with mellow to direct AD matured in the vicinity of 65 and 80 years [11]. There were no noteworthy contrasts between salvia officinalis and fake treatment as far as the watched symptoms. What's more, salvia officinalis may decrease fomentation in patients. All the more excellent extensive scale randomized controlled trials are required, be that as it may, for advance assurance of the herb's adequacy [11].

Herbal formulations or mixtures of herbal ingredients

Herbal formulations or blends of herbal fixings may have preferences with different target control contrasted and the single target enemy in the perspective of customary Chinese medication, in spite of the fact that there have been couple of clinical trials looking at the adequacy and security of natural details in AD patients.

Shenwu case, a blend of six herbs that is thought to lessen amyloid cytotoxicity, expanded the memory score from gauge ($n = 83$) - however without critical contrast from aniracetam ($n = 83$) - in a 12-week stage II trial for patients with mellow subjective disability [12]. A stage III trial is currently in progress. Stillbene glycoside, a concentrate of Shenwu container, has been assessed in a stage I trial for AD. Additionally comes about for both of these details will be accessible in the following couple of years.

GEPT, a blend of five dynamic parts removed from Chinese herbs, might be profitable for the treatment of AD - lessening the level of A β by means of the hindrance of γ -secretase (presenilin-1) and the advancement of insulin-debasing catalyst and neprilysin, which has been accounted for in the cerebrum of APPV717I transgenic mice [13]. A 24-week preparatory investigation of GEPT demonstrated a noteworthy change on intellectual capacity in patients with amnesic mellow subjective weakness, a beginning time of AD ($n = 101$), reliably crosswise over various psychological scales; for instance, a change in the ADAS intellectual subscale from standard of - 4.19 focuses (95% certainty interim = - 5.74 to - 2.63), which declined at 24 weeks of follow-up after the GEPT withdrawal. This level of viability was practically identical with that of - 4.23 focuses found in the subjects taking Donepezil ($n = 100$) (Figure 1) [14]. GEPT

is wanted to apply for a shape II trial.




Figure 1 : Cognitive function in patients with amnesic mild cognitive impairment

Mean difference in the Alzheimer Disease Assessment Scale intellectual subscale (ADAS-opinion) score from standard after treatment in patients with amnesic mellow psychological debilitation (aMCI). ITT-LOCF, Intent to Treat populace Using the Last Observation Carried Forward Method.

Besides, the home grown arrangements Ba Wei Di Huang Wan and Yi-Gan San are exclusively

answered to essentially enhance cognizance or conduct and capacity on the Mini-Mental State Examination, the Neuropsychiatric Inventory and the Barthel Index in the patients with AD [15,16].

Conclusion

Single herbs or plants might have the capacity to supplement affirmed drugs for AD. No genuine unfavourable occasions have been accounted for. The present confirmation to help their utilization alone, be that as it may, is uncertain or insufficient. This vulnerability is for the most part caused by methodological confinements, for example, poor examination outline, moderately little specimen sizes without a power count, improper result measures and essential and auxiliary end-point determination, and invalid factual investigation. Moreover, the herbs' potential incentive for counteractive action and treatment of AD just outcomes from symptomatic changes and short treatment periods (< a half year). A few examinations at present in progress or in beginning time improvement in China to assess herb blends will ideally indicate promising outcomes sooner rather than later.

References

1. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, Memantine Study Group: Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2003; 348: 1333-1341. 10.1056/NEJMoa013128.View ArticlePubMedGoogle Scholar
2. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEM-MD-12 Study Group: Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. *Curr Alzheimer Res*. 2008; 5: 83-89. 10.2174/156720508783884576.View ArticlePubMedGoogle Scholar
3. Birks J, Grimley Evans J: Ginkgo biloba for cognitive impairment and dementia. *Cochrane Database Syst Rev*. 2009; 1: CD003120-PubMedGoogle Scholar
4. Mazza M, Capuano A, Bria P, Mazza S: Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. *Eur J Neurol*. 2006; 13: 981-985. 10.1111/j.1468-1331.2006.01409.x.View ArticlePubMedGoogle Scholar
5. Snitz BE, O'Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, Saxton J, Lopez OL, Dunn LO, Sink KM, DeKosky ST: Ginkgo Evaluation of Memory Study I: Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. *JAMA*. 2009; 302: 2663-2670. 10.1001/jama.2009.1913.PubMed CentralView ArticlePubMedGoogle Scholar
6. Li J, Wu HM, Zhou RL, Liu GJ, Dong BR: Huperzine A for Alzheimer's disease. *Cochrane Database Syst Rev*. 2008; 2: CD005592-PubMedGoogle Scholar
7. Zhang Z, Wang X, Chen Q, Shu L, Wang J, Shan G: Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial [in Chinese]. *Zhonghua Yi Xue Za Zhi*. 2002; 82: 941-944.PubMedGoogle Scholar
8. Chen F, Eckman EA, Eckman CB: Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. *Faseb J*. 2006; 20: 1269-1271.

- 10.1096/fj.05-5530ffe.View ArticlePubMedGoogle Scholar
9. Fu LM, Li JT: A systematic review of single Chinese herbs for Alzheimer's disease treatment. *Evid Based Complement Alternat Med*. 2009,Google Scholar
10. Lee MS, Yang EJ, Kim JJ, Ernst E: Ginseng for cognitive function in Alzheimer's disease: a systematic review. *J Alzheimers Dis*. 2009, 18: 339-344.PubMedGoogle Scholar
11. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M: *Salvia officinalis* extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebocontrolled trial. *J Clin Pharm Ther*. 2003, 28: 53-59. 10.1046/j.1365-2710.2003.00463.x.View ArticlePubMedGoogle Scholar
12. Zhong J, Tian JZ, Zhu AH, Yang CZ: Clinical study on a randomized, doubleblind control of Shenwu gelatin capsule in treatment of mild cognitive impairment [in Chinese]. *Zhongguo Zhong Yao Za Zhi*. 2007, 32: 1800-1803.PubMed Google Scholar
13. Tian J, Shi J, Zhang L, Yin J, Hu Q, Xu Y, Sheng S, Wang P, Ren Y, Wang R, Wang Y: GEPT extract reduces a beta deposition by regulating the balance between production and degradation of amyloid-beta in APPV717I transgenic mice. *Curr Alzheimer Res*. 2009, 6: 118-131. 10.2174/156720509787602942.View ArticlePubMed Google Scholar
14. Miao YC: Part 5: a randomized, double-blind and parallel control study of GEPT extract in the treatment of amnesic mild cognitive impairment. PhD thesis. 2008, Beijing University of Chinese Medicine, 95-117.Google Scholar
15. Iwasaki K, Kobayashi S, Chimura Y, Taguchi M, Inoue K, Cho S, Akiba T, Arai H, Cyong JC, Sasaki H: A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine 'Ba wei di huang wan' in the treatment of dementia. *J Am Geriatr Soc*. 2004, 52: 1518-1521. 10.1111/j.1532-5415.2004.52415.x.View ArticlePubMed Google Scholar
16. Iwasaki K, Satoh-Nakagawa T, Maruyama M, Monma Y, Nemoto M, Tomita N, Tanji H, Fujiwara H, Seki T, Fujii M, Arai H, Sasaki H: A randomized, observer blind, controlled trial of the traditional Chinese medicine yigan san for improvement of behavioural and psychological symptoms and activities of daily living in dementia patients. *Clinical Psychiatry*. 2005, 66: 248-252. 10.4088/JCP.v66n0214.View ArticlePubMed Google Scholar
17. Lee ST, Chu K, Sim JY, Heo JH, Kim M: Panax ginseng enhances cognitive performance in Alzheimer disease. *Alzheimer Dis Assoc Disord*. 2008, 22: 222-226. 10.1097/WAD.0b013e31816c92e6.View ArticlePubMed Google Scholar